Regeneron Pharmaceuticals, Inc. (REGN) financial statements and ratios from SEC XBRL: revenue $14.34B (TTM), net margin 31.4%, revenue growth 1.0% YoY, P/E 20.8. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $14.34B |
| Net Margin | 31.4% |
| Revenue Growth (YoY) | 1.0% |
| EPS Growth (YoY) | 5.3% |
| FCF Growth (YoY) | 11.3% |
| P/E Ratio | 20.8 |
| EV / EBITDA | 19.4 |
| Price / Book | 2.76 |
| Price / Sales | 5.75 |
| FCF Yield | 7.2% |
| DCF Value (model) | $661.80 |
| DCF Upside vs Price | -20.0% |
| Altman Z-Score | 8.08 (safe) |
| Sector P/E (Healthcare) | 21.6 |
REGN overview · REGN earnings · REGN KPIs · REGN investor relations · REGN ownership · REGN peers · REGN filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.